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Abstract
Background: The immunological status, consisting of “inflammation status” and “nutritional condition,” is important
for the survival of patients with various cancers, including non-small cell lung cancer (NSCLC). The neutrophil/
lymphocyte ratio (NLR) reflects the inflammation status, and the prognostic nutritional index (PNI) reflects the
immunological nutritional condition. In the present study, the correlation between the NLR and the PNI as well as
the consistency and magnitude of the prognostic impact of the NLR and the PNI were investigated.
Methods: We conducted a retrospective review of data from 334 patients who had undergone a curative resection
for NSCLC. The NLR and the PNI were calculated, which was routinely performed before surgery. The correlations
between the NLR and the PNI and survival were then evaluated.
Results: A clear inverse correlation was observed between the NLR and the PNI. The NLR was associated with sex,
smoking history, the CEA level, tumor size, and vascular invasion. The PNI was associated with sex, age, smoking
history, tumor size, histological type, tumor differentiation, and vascular invasion. Patients with NLR ≥2.5 had a
significantly poorer survival outcome, and patients with PNI <50 had a significantly poorer survival outcome. A
multivariate analysis demonstrated that age, nodal metastasis, tumor differentiation, NLR, and PNI were
independent predictors of disease-free and overall survival.
Conclusions: Our study demonstrated a significant inverse correlation between the NLR and the PNI, and a high
NLR and a low PNI were significantly associated with a poor survival among patients who had undergone a
complete resection for NSCLC.
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Background
Lung cancer is a major cause of death in many devel-
oped countries. Surgical resection continues to play an
important role in the treatment of this disease, especially
during the early stages of non-small cell lung cancer
(NSCLC). Over the past few decades, a number of prog-
nostic factors for NSCLC patients following resection
have been investigated. Until now, the anatomic extent
of the tumor (TNM classification) has been regarded as
the most powerful tool for predicting patient prognosis
[1]. On the other hand, several biomarkers have been re-
ported as predictors of survival and recurrence: (1)
clinical factors (e.g., sex, age, or performance status); (2)
pathological factors (e.g., histological subtype, cell differ-
entiation, or visceral pleural invasion; and (3) many bio-
logical factors involved in cancer development and
progression [2, 3].
Recently, several investigators have reported that the
immunological status, consisting of the “inflammation
status” and the “nutritional condition,” is important for
the survival of patients with various cancers, including
NSCLC. First, increasing evidence regarding the “inflam-
mation status” has shown that the systematic inflamma-
tory response has prognostic value for patients with
various cancers [4, 5]. In particular, the neutrophil/
lymphocyte ratio (NLR) has been recognized as a pre-
dictor of a poor prognosis. For NSCLC, several reports
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have described evidence of the prognostic value of the
NLR [6–12]. Second, evidence regarding the impact of
the “nutritional condition” has also been increasing.
Above all, the prognostic nutritional index (PNI), which
is calculated by combining the serum albumin concen-
tration with the total peripheral blood lymphocyte
count, was initially used to assess the immune-
nutritional status of patients receiving gastrointestinal
surgery [13]. Several reports have been shown that the
PNI is a prognostic marker in patients with various can-
cers, including cancer of the esophagus, stomach, colo-
rectal, pancreas, and malignant pleural mesothelioma
[14–18]. Moreover, the PNI can predict the prognosis of
patients with cancer regardless of the site of origin [19].
However few studies examining the PNI in patients with
NSCLC have been performed [20].
To our knowledge, the clinical impacts of both the
NLR and the PNI have not yet been investigated simul-
taneously. In the present study, we investigated the cor-
relation between the NLR and the PNI as well as the
consistency and magnitude of the prognostic impact of
the NLR and the PNI among patients who had under-
gone a complete resection for NSCLC.
Methods
Patient population
We conducted this retrospective study in a total of 334
patients with NSCLC who underwent surgery at the
Kawasaki Medical School Hospital between 2007 and
2012. All the patients included in the analysis met the
following criteria: (1) curative resection (segmentectomy
or lobectomy) with lymph node dissection; (2) neither
radiotherapy nor chemotherapy administered prior to
the surgery; and (3) preoperative NLR and PNI obtained
before surgery. The histological diagnosis of the tumors
was based on the criteria of the World Health
Organization, and the TNM stage was determined ac-
cording to the criteria established in 2009. This study
was conducted with the approval of the institutional
Ethics Committee of Kawasaki Medical School (No.
1803: approved on May 12, 2014).
NLR and PNI evaluation
The NLR and the PNI were calculated using data from a
complete blood count that was routinely performed be-
fore surgery. The receiver operating characteristic (ROC)
curves identified a NLR cutoff value of 2.5 for predicting
recurrence in patients (area under the curve (AUC) =
0.63, 95 % CI: 0.56–0.69, P < 0.001). In addition, based
on a previous study, the data were dichotomized using a
NLR cutoff value of 2.5 [10]. The PNI was calculated as
10 × serum albumin (g/dL) + 0.005 × total lymphocyte
count (per millimeter) [13]. The PNI value of at least
50 was defined as normal, while less than 50 was
regarded as mild malnutrition, less than 45 was regarded
as moderate to severe malnutrition, and less than 40 was
regarded as serious malnutrition [15]. The cutoff value
of the PNI for clinically significant malnutrition was set
at below 50 in this study.
Follow-up
The follow-up examination schedule was arranged on
an individual basis; most of the patients received
medical check-ups and chest x-ray films or CT scans
at least twice per year. The last follow-up review was
performed on June 30, 2014. The median follow-up
duration for the detection of disease-free survival
(DFS) or overall survival (OS) was 32.0 months (range
3–72 months).
Statistical analysis
All the statistical analyses were performed using the
SPSS statistical package (version 17.0; SPSS, Chicago, IL).
Categorical data were examined using the χ2 test. ROC
Table 1 Association between NLR/PNI value and
clinicopathological findings
Number NLR PNI
All cases 334 2.52 ± 2.06 51.03 ± 5.72
Age
≦70 165 2.34 ± 1.91 52.20 ± 5.38*
>70 169 2.69 ± 2.18 49.59 ± 5.70*
Smoking history
Never 122 2.27 ± 1.69 52.32 ± 5.00**, ***
Former 116 2.69 ± 2.41 49.70 ± 5.65**
Current 95 2.64 ± 1.99 50.97 ± 6.36***
Histology
Adenocarcinoma 231 2.43 + 2.07 51.87 + 5.17****
Squamous cell carcinoma 69 2.80 + 2.30 48.22 + 6.49****
Large cell carcinoma 22 2.84 + 1.42 49.55 + 6.38
Adenosquamous carcinoma 6 2.01 + 0.61 52.49 + 2.39
Pleomorphic carcinoma 6 1.90 + 0.93 55.07 + 6.92
Tumor differentiation
Well 118 2.39 + 2.12 51.82 + 4.70
Moderate 115 2.55 + 2.29 50.96 + 6.12
Poor 101 2.59 + 1.70 50.23 + 6.30
Pathological stage
IA 144 2.40 + 2.13 51.74 + 5.33
IB 95 2.54 + 1.68 50.30 + 6.00
IIA+IIB 55 2.60 + 2.21 50.30 + 5.50
IIIA+IIIB 40 2.75 + 2.37 51.18 + 6.58
NLR neutrophil/lymphocyte ratio, PNI prognostic nutritional index
*, **, ****p < 0.01
***p < 0.05
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curves of the NLR and PNI for the prediction of DFS or
OS were generated to determine the cutoff value that
yielded an optimal sensitivity and specificity. The prognos-
tic evaluation was performed by considering the OS and
DFS, which was defined as the time until lung cancer re-
currence, the occurrence of a second cancer, or non-lung
cancer-related death. The survival curves were estimated
using the Kaplan-Meier method, and differences
among the curves were evaluated using the log-rank
test. Univariate and multivariate analyses were per-
formed using the Cox proportional hazards model.




The patients ranged in age from 46 to 88 years (mean,
69.3 years). There were 219 men and 115 women. The
majority of patients (231, 69.1 %) had adenocarcinoma,
while 69 (20.7 %) had squamous cell carcinoma, 22
(6.6 %) had large cell carcinoma, and 12 (3.6 %) had
other histological types. Pathological N0 disease was
confirmed in 270 patients (80.8 %), and N1 or N2 dis-
ease was confirmed in 64 patients (19.2 %). Pathological
stage I disease was confirmed in 239 patients (71.5 %),
and stage II or stage III disease was confirmed in 95
patients (28.5 %).
Association between NLR/PNI value and clinicopathological
findings
The NLR values of the patients ranged from 0.67 to
15.49 (mean, 2.52; median, 1.97). The mean NLR was
not associated with age, smoking history, histological
type, tumor differentiation, or pathological stage. On the
other hand, the PNI values of the patients ranged from
28.20 to 65.25 (mean, 51.0; median, 50.80). The mean
PNI was significantly lower among patients who were
older, former and current smokers, and those with squa-
mous cell carcinoma (Table 1). A significant inverse cor-
relation was observed between the NLR and PNI values
(r = −0.490, P < 0.001) (Fig. 1).
Clinicopathological characteristics grouped according to
NLR and PNI statuses
We used an ROC curve analysis to evaluate whether the
NLR and PNI could predict DFS or OS (Fig. 2). The
ROC curves identified an optimal NLR cutoff value of 2.5
for predicting DFS or OS in patients (DFS; AUC = 0.63,
P = 0.001, OS; AUC= 0.62, P = 0.002). The ROC curves
identified an optimal PNI cutoff value of 50 for predicting
DFS or OS in patients (DFS; AUC = 0.62, P = 0.001, OS;
AUC = 0.64, P < 0.001). We divided the patient population
based on a NLR and PNI cutoff value of 2.5 and 50 for the
patients. All the clinicopathological characteristics were
comparable between patients according to their NLR or
Fig. 1 Correlation between the NLR and the PNI (r = −0.490, P < 0.001)
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PNI statuses (Table 2). Our study showed that the NLR
was associated with sex, smoking history, the CEA level,
tumor size, and vascular invasion. On the other hand, the
PNI was associated with sex, age, smoking history, tumor
size, histological type, tumor differentiation, and vascular
invasion. Interestingly, nodal metastasis was not associ-
ated with either the NLR or the PNI.
Surgical factors and recurrence grouped by NLR and PNI
status
The surgical factors and recurrence were comparable be-
tween patients according to their NLR or PNI statuses
(Table 3). In this study, no patient had received pneu-
monectomy because all patients who had gone pneu-
monectomy between 2007 and 2012 had received induction
Fig. 2 Receiver operating characteristics (ROC) curve for predicting disease-free survival (DFS) or overall survival (OS). DFS-NLR: AUC 0.63(95 % CI
0.56–0.69) P = 0.001. OS-NLR: AUC 0.62 (95 % CI 0.54–0.69) P = 0.002. DFS-PNI: AUC 0.62 (95 % CI 0.55–0.68) P = 0.001. OS-PNI: AUC 0.64 (95 % CI
0.57–0.72) P < 0.001
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chemotherapy or chemoradiotherapy and excluded from this
study. Significant associations of the NLR ≥2.5 or PNI <50
were observed with the rate of thoracotomy (P= 0.044) but
not with the type of resection (P= 0.997). Significant associa-
tions of the NLR ≥2.5 or PNI <50 were observed with the
rate of recurrence; however, significant associations were not
observed with the first recurrence site (local or distant
metastasis).
Prognostic analysis
The 3-year DFS was 71.5 % in this study. Patients with
NLR ≥2.5 had a significantly poorer survival outcome,
compared with those with NLR < 2.5 (78.7 vs. 58.0 %,
P < 0.001, according to the log-rank test; Fig. 3a). On
the other hand, patients with PNI <50 had a signifi-
cant poorer survival outcome, compared with those
with PNI ≥50 (80.4 vs. 58.3 %, P < 0.001, according to
the log-rank test; Fig. 3b). A univariate analysis
showed that age, tumor size, nodal metastasis, tumor
differentiation, the NLR, and the PNI were predictors
of the DFS. A multivariate analysis was then performed
using the Cox proportional hazards model. Using this
model, we demonstrated that age (P = 0.004) and nodal
metastasis (P < 0.001), tumor differentiation (P = 0.047),
the NLR (P = 0.039), and the PNI (P = 0.007) were inde-
pendent predictors of the DFS (Table 4). Overall survival
(OS) data are immature, but a multivariate analysis
suggested that age, nodal metastasis, NLR, and PNI
were independent predictors of OS (Table 4).
Discussion
To our knowledge, this is one of the largest studies to
evaluate the value of NLR and/or PNI in predicting the
outcome of patients with NSCLC. In addition, this is the
first study to show a correlation between the NLR and the
PNI, as well as the prognostic impact of both the NLR
and the PNI among patients with NSCLC. Our study
demonstrated a positive correlation between the NLR and
the PNI, and a high NLR (≥2.5 vs. <2.5, P = 0.039) and a
low PNI (<50 vs. ≥50, P = 0.007) were significantly associ-
ated with a poor survival in the multivariate analysis.
Table 2 Clinicopathological characteristics grouped by NLR and
PNI status
Cases NLR PNI
<2.5 ≥2.5 P value <50 ≥50 P value
Sex
Female 121 88 33 0.038 36 85 0.002
Male 213 131 82 100 113
Age
≦70 165 116 49 0.072 45 120 <0.001
>s70 169 103 66 91 78
Smoking history
Never 123 90 33 0.026 39 84 0.010
Smoker 211 129 82 97 114
CEA
Normal 231 165 66 0.001 87 144 0.089
High 103 54 49 49 54
Tumor size
T1 161 116 45 0.016 51 110 0.001
T2 + 3 173 103 70 85 88
Nodal metastasis
Negative 270 181 89 0.246 110 160 0.986
Positive 64 38 26 26 38
Histological type
Adenoca 231 159 72 0.060 81 150 0.002
Non-adenoca 103 60 43 55 48
Tumor differentiation
Well 118 85 33 0.066 39 79 0.035
Mod + por 216 134 82 97 119
Vascular invasion
Negative 190 139 51 0.001 68 122 0.035
Positive 144 80 64 68 76
NLR –
<2.5 220 – – 54 165 <0.001
≥2.5 114 – – 82 33
PNI –
<50 136 54 82 <0.001 – –
≥50 198 165 33 – –
NLR neutrophil/lymphocyte ratio, PNI prognostic nutritional index, adenoca
adenocarcinoma, mod+por moderate+poorly
Table 3 Surgical factor and recurrence grouped by NLR and
PNI status
Cases NLR PNI
<2.5 ≥2.5 P value <50 ≥50 P value
Type of resection
Segmentectomy 33 17 0.997 20 30 0.959
Lobectomy 186 98 135 196
Surgical Approach
VATS 142 64 0.044 74 132 0.005
Thoracotomy 77 51 62 66
Recurrence
Negative 173 77 0.016 90 160 0.003
Positive 46 38 46 38
First recurrence site
Local 15 12 0.154 11 16 0.193
Distant 24 19 27 16
Both 7 7 8 6
NLR neutrophil/lymphocyte ratio, PNI prognostic nutritional index, VATS
video-assisted thoracic surgery
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The NLR is an inexpensive, reproducible, and widely
available blood test. The preoperative NLR reflects the
inflammation status and has been found to be an
important indicator of an adverse prognosis among pa-
tients with various cancers. In resected NSCLC, Sarraf et
al. reported that an increased preoperative NLR was
Fig. 3 a Kaplan-Meier disease-free survival curve according to the NLR: log-rank P < 0.001. b Kaplan-Meier disease-free survival curve according to
the PNI: log-rank P < 0.001
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associated with a higher stage and remained an independ-
ent predictor of overall survival [8]. Accumulating evi-
dence supports the involvement of systemic inflammation
in cancer progression. Cancer-related inflammation in-
cludes the presence of inflammatory cells and mediators
in the tumor microenvironment. Neutrophils are a major
constituent of cancer-related inflammation as well as the
host defense against bacterial infection. Tumor-associated
neutrophils can function as immunosuppressive cells in
the presence of tumors [21]. On the other hand, circulat-
ing neutrophils have been shown to produce cytokines
that contribute to cancer progression, and an elevated
number of neutrophils suppress lymphokine-activated
killer cells, thereby increasing the propensity for metasta-
sis [22, 23]. Thus, the systemic inflammatory response has
been associated with a poorer prognosis among patients
with various cancers including NSCLC.
Patients with an elevated NLR exhibit a relative lympho-
cyte ratio and may have a poorer lymphocyte-mediated
immune response to tumors, thereby increasing tumor
progression and worsening the prognosis [24]. In this re-
gard, the NLR seems to be a potential indicator mirroring
both host immunity and neutrophil-dependent inflam-
mation, which is associated with the clinical outcome.
Particularly, in patients who had undergone a complete
resection of the main tumor, the host cell-mediated im-
munity continues to exert important effects on the de-
struction of residual tumor cells and micrometastasis.
Accordingly, a higher NLR was found to be associated
with a poor DFS.
Assessment and support of the nutritional status
should be considered a valuable component of the over-
all oncological strategy [25]. The PNI was reported by
Smale et al. to predict the risk of operative morbidity
and mortality after gastrointestinal surgery [26]. How-
ever, their method for calculating the PNI was too diffi-
cult to use routinely. In contrast, the simplified PNI
reported by Onodera et al. was based on only two la-
boratory parameters, the albumin level and the lympho-
cyte count, which can be easily measured and are
routinely used in clinical practice [13]. The PNI was
initially designed to assess the nutritional and immuno-
logical statuses of patients undergoing gastrointestinal
surgery. In 2011, Proctor et al. reported that Onodera’s
PNI could predict the outcome of cancer patients, re-
gardless of the primary site of origin [19]. However, to
our knowledge, few studies have examined the PNI in
patients with NSCLC. In patients with lung cancer, a
smoking habit is frequently associated with malnutri-
tion. Chronic obstructive pulmonary disease (COPD)
and aging are independent and probably concurrent
conditions leading to malnutrition [27]. Shinozawa et
al. reported that cigarette smoking and an advanced age
were well-known risk factors for COPD, and a lower
lung function was independently and linearly associated
with lower blood markers for nutritional status and
anemia [28]. In our study, the mean PNI was signifi-
cantly lower among older patients, former and current
smokers, and those with squamous cell carcinoma. In
patients with lung cancer, the PNI is probably associ-
ated not only with the immunological status but also
with cigarette smoking.




HR 95 % CI P value HR 95 % CI P value
Sex
Male/female 1.70 1.08–2.69 0.023 1.37 0.85–2.19 0.187
Age
>70/≦70 2.42 1.58–3.71 <0.001 1.94 1.24–3.04 0.004
Tumor size
T2–3/T1 2.25 1.47–3.45 <0.001 1.14 0.74–1.76 0.560
Nodal metastasis
Positive/negative 6.50 4.30–9.80 <0.001 6.42 4.16–9.89 <0.001
Histological type
AD/non-AD 1.45 0.95–2.20 0.083 0.72 0.46–1.13 0.150
Tumor differentiation
Mod+por/well 2.71 1.65–4.44 <0.001 1.69 1.01–2.83 0.047
NLR
≥2.5/<2.5 2.09 1.40–3.12 <0.001 1.58 1.02–2.43 0.039
PNI
<50/≥50 2.28 1.52–3.42 <0.001 1.88 1.19–2.97 0.007
Overall survival
Sex
Male/female 1.76 1.04–2.97 0.035 1.19 0.67–2.10 0.554
Age
>70/≦70 3.54 2.07–6.05 <0.001 2.31 1.30–4.08 0.004
Tumor size
T2-3/T1 2.60 1.56–4.31 <0.001 1.45 0.85–2.46 0.171
Nodal metastasis
Positive/negative 4.21 2.62-6.74 <0.001 3.78 2.34–6.13 <0.001
Histological type
AD/non-AD 1.20 1.05–1.36 0.006 1.07 0.92–1.24 0.373
Tumor differentiation
Mod+por/well 2.81 1.59–4.99 <0.001 1.60 0.85–3.02 0.143
NLR
≥2.5/<2.5 1.81 1.14–2.87 0.012 1.60 1.04–2.54 0.048
PNI
<50/≥50 3.37 2.07–5.48 <0.001 2.40 1.39–4.14 0.002
NLR neutrophil/lymphocyte ratio, PNI prognostic nutritional index, AD
adenocarcinoma, mod+por moderate+poorly
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This study has several limitations that should be con-
sidered when interpreting the results. The retrospective
study design was a major limitation of the present study.
Minor limitations included insufficient evidences of the
validity of the cutoff values for the NLR and the PNI.
Regarding the NLR, a fixed cutoff value has not yet been
established, and various values have been used in previ-
ous reports. Because many studies did not describe the
method used to select the NLR cutoff, we used a cutoff
value based on a previous study. Regarding the PNI,
fixed cutoff value has also not yet been established, and
various values have been used in previous reports.
Conclusions
In conclusion, a significant inverse correlation between
the NLR and the PNI and a high NLR and a low PNI
were significantly associated with a poor survival among
patients who had undergone a complete resection for
NSCLC. NLR and PNI may help in assessing the treat-
ment strategy such as adjuvant therapy and the examin-
ation interval after surgery.
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